Protocol Ledger

NCT07121413 · Phase II · RECRUITING

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

Interventional Phase II clinical trial protocol NCT07121413 sponsored by Shanghai Synvida Biotechnology Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-04 Enrollment: 48 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07121413
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07121413
Protocol FieldVerified Registry Value
NCT IdentifierNCT07121413
Consolidated Lead SponsorShanghai Synvida Biotechnology Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment48 participants (ESTIMATED)
Registered Start Date2025-11-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI